Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

NAAS RATING: 5.23, Impact Factor: RJIF 5.98 | Free Publication Certificate
updates
NAAS Rating: 5.23 new
Vol. 3, Issue 12 (2015)

Colon targeting of ornidazole and curcumin inclusion complex a novel approach in inflammatory bowel disease

Author(s):
Sukhbir Kaur, Lavleen Kaur
Abstract:
The present investigation was planned to formulate tablets of ornidazole and curcumin which are targeting the drug directly to colon for the treatment of inflammatory bowl disease (IBD). Inclusion complex of the drugs with β-cyclodextrin were prepared by kneading method. The 10% coating concentration of eudragit S100 shows the complete release of the drugs to colon for the treatment of IBD. Coating concentration we designed based on the full factorial design. In-vitro release was conducted for all the formulations in USP appratus 1, i.e. basket type for 24 h in different ph resembling different portions of gastro intestinal tract. In vitro dissolution studies, it was found that formulation F4 showed 99.43% of ornidazole in 24 hours and 93.14% of curcumin in 24 hours, which lies in within the acceptance criteria. That study conclude that 10% coating concentration of eudragit S100 shows the complete release of drugs to colon for treatment of inflammatory bowl disease (IBD).
Pages: 94-98  |  869 Views  10 Downloads
How to cite this article:
Sukhbir Kaur, Lavleen Kaur. Colon targeting of ornidazole and curcumin inclusion complex a novel approach in inflammatory bowel disease. Pharma Innovation 2015;3(12):94-98.
The Pharma Innovation Journal